The Turkel Method: The Down’s Syndrome Diet and Nutritional Supplements
Dr. Turkel worked for years to get his Down Syndrome cure approved by the FDA but without success...not because it wasn't safe or effective but because the FDA works to support the profitability of Big Pharma instead of patients.Dr. Turkel worked for decades to cure Down’s syndrome using nutrition and orthomolecular medicine. His method involves nutrient combinations that he called the “U Series”. When he developed his system many decades ago, he sent patients to a compounding pharmacy to have the pharmacists produce this customized treatment. Today, patients can contact Dixie Lawrence-Tafoya to get a compounding pharmacy to produce similar products: Click here to go to a compounding pharmacy to produce the U-Series at home therapy for Down’s syndrome.
How Dr. Turkel’s Cure for Down’s Syndrome Was Hidden and Restricted by the FDA
Though Dr. Turkel had great success at being able to reduce symptoms of Down syndrome using diet and nutrition, he tried to get his Down’s syndrome treatment method FDA-approved, but ran into the same political quagmire that happens to doctors and scientists who discover cures for cancer. The FDA informed Dr. Turkel that a combination of medicines (in Dr. Turkel’s case, nutrients that were being used medicinally), constituted a “new drug” that had to be approved by the FDA for shipment across state lines. The “new drug” must be deemed “safe” in order for him to ship across state lines.
Dr. Turkel’s formulation was, in fact, designated as “safe”.
The FDA at this time was responsible for labeling medications to ensure that the labels were accurate. But the FDA claimed that Dr. Turkel had not provided “adequate labeling” for his Down’s syndrome cure. The FDA didn’t specify what was wrong with Dr. Turkel’s labeling so Dr. Turkel was not able to fix the problem. In a communication between Dr. Turkel and the FDA in 1960, Mr. Yakowitz from the Bureau of Enforcement sent a message to Dr. Turkel saying that it was doubtful that Dr. Turkel’s medicinal formula could benefit Down’s syndrome because:
“...the condition is caused by a defect in the basic cell structure. This finding considered together with the long history of inability of medical science to find a treatment or cure for mongolism [Down Syndrome] suggests that this condition is beyond hope of successful treatment by the kind of preparations that you wish to recommend for this purpose.”
Mr. Yakowitz also stated that:
“....the proposed mixture of pentylenetetrazol with nicotinic acid is regarded as unscientific.”
Pentylenetetrazol with nicotinic acid was approved for use by various pharmaceutical companies at that time, but the FDA wanted to stall on the approval of Dr. Turkel’s Down’s syndrome medicine to reduce symptoms of the disease. They were trying to delay a possible FDA-approval of Dr. Turkel’s medicine long enough to fabricate a public hysteria about developmental delays which came about soon after with the thalidomide tragedies. After thalidomide, medical staff at the FDA got Congress to make Amendments requiring “proof” of efficacy of any new drug. “Proof”, however, was defined arbitrarily by the FDA to protect certain disease “industries” that are especially profitable.
NOTE: Readers should know that nicotinic acid, also known as vitamin B3 or niacin is sometimes also administered today a Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN) to produce Nicotinamide Adenine Diphosphate (NAD+). Rather than combining nicotinic acid and pentylenetetrazol (to improve absorption of the nicotinic acid), Down’s syndrome patients may instead benefit from taking oral NMN (which is not available in the United States) or oral NR (a suitable alternative). Down’s syndrome patients can also receive NAD+ injections or use an NAD+ nasal spray to increase levels of this vital nutrient that improves cognition significantly.
Click here to learn more about the AlivenHealthy Living Database.
By 1963, Dr. Turkel received the following communication from the FDA:"It is our opinion that it may be impossible to write suitable labeling for the efficacy of this product; in view of the cytogenetic basis of mongolism [Down’s syndrome], we recommend that you abandon work on this application."
In fact, it is nearly impossible to write labeling for the role played by each individual nutrient in Dr. Turkel’s formula because they work synergistically in the body. As such, Dr. Turkel was required to write adequate labeling for his drug’s effectiveness, but the FDA regulations were worded such that it was impossible to write adequate labeling.
In 1963, Dr. Turkel was also invited by the FDA to provide more evidence for the effectiveness of his drug, but the FDA also warned him simultaneously that it would be “difficult” for him to create a plan that the FDA would approve. One year later, the FDA sent Dr. Turkel the following order:
"You should immediately recall the drug from all clinical investigators and discontinue administering it to human beings."
Under the 1962 laws set forth by the FDA against Dr. Turkel, it would have been impossible to approve penicillin or aspirin, but by the time Dr. Turkel’s cure for Down’s syndrome was submitted for approval, Big Pharma had already taken shape to prevent the public from learning about cures for serious diseases. Rather, Big Pharma was, at this time, working to produce profitable drug industries around diseases like Down’s syndrome. As a result, Dr. Turkel’s Down syndrome cure was never approved and it never became well-known or available to the masses in the United States. However, the Russians found out about the U-Series as a potential cure for Down’s Syndrome in 1961 and adopted its use and it was widely available in both Japan and Norway since 1964. In Norway, it was dispensed by all physicians at 80 university and national hospitals for the treatment of Down’s syndrome, learning disability, and developmental delays.
Click here to read a detailed overview of Dr. Turkel's cure for Down Syndrome.
Resources:
• LifeExtension Magazine (2023). The Untapped Healing Potential of DMSO. Retrieved March 14, 2024 from https://www.lifeextension.com/magazine/2007/7/cover_dmso
• Leshin, L. (1998). Dimethyl Sulfoxide (DMSO) and Down Syndrome. Retrieved March 14, 2023 from https://www.ds-health.com/dmso.htm
• Drachmann, D. et al. (2020). Ketotic hypoglycemia in patients with Down Syndrome. Retrieved March 14, 2024 from https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmd2.12241
• Jiang, Y. et al. (2019). Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99). Retrieved March 14, 2024 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607756/
• Turkel, H. et al. (1974). Medical Amelioration of Down's Syndrome Incorporating the Orthomolecular Approach. Retrieved March 14, 2024 from http://orthomolecular.org/library/jom/1975/pdf/1975-v04n02-p102.pdf
• ISOM (2023). Henry Turkel, MD. Retrieved March 26, 2024 from https://isom.ca/profile/henry-turkel/
• Turkel, et al. (1975). Intellectual Improvement of A Retarded Patient Treated with the "U" Series. Retrieved March 26, 2024 from http://orthomolecular.org/library/jom/1984/pdf/1984-v13n04-p272.pdf
• Irgens, H. U. et al. (2015). Glycogenin-2 is dispensable for liver glycogen synthesis and glucagon-stimulated glucose release. Retrieved March 26, 2024 from https://pubmed.ncbi.nlm.nih.gov/25751106/
BEFORE YOU READ THIS ARTICLE...
Be sure to take a look at a few of our e-Books titles below that might pertain to your health search:
Be sure to take a look at a few of our e-Books titles below that might pertain to your health search:
The Turkel Method: The Down’s Syndrome Diet and Nutritional Supplements
Dr. Turkel worked for years to get his Down Syndrome cure approved by the FDA but without success...not because it wasn't safe or effective but because the FDA works to support the profitability of Big Pharma instead of patients.Dr. Turkel worked for decades to cure Down’s syndrome using nutrition and orthomolecular medicine. His method involves nutrient combinations that he called the “U Series”. When he developed his system many decades ago, he sent patients to a compounding pharmacy to have the pharmacists produce this customized treatment. Today, patients can contact Dixie Lawrence-Tafoya to get a compounding pharmacy to produce similar products: Click here to go to a compounding pharmacy to produce the U-Series at home therapy for Down’s syndrome.
How Dr. Turkel’s Cure for Down’s Syndrome Was Hidden and Restricted by the FDA
Though Dr. Turkel had great success at being able to reduce symptoms of Down syndrome using diet and nutrition, he tried to get his Down’s syndrome treatment method FDA-approved, but ran into the same political quagmire that happens to doctors and scientists who discover cures for cancer. The FDA informed Dr. Turkel that a combination of medicines (in Dr. Turkel’s case, nutrients that were being used medicinally), constituted a “new drug” that had to be approved by the FDA for shipment across state lines. The “new drug” must be deemed “safe” in order for him to ship across state lines.
Dr. Turkel’s formulation was, in fact, designated as “safe”.
The FDA at this time was responsible for labeling medications to ensure that the labels were accurate. But the FDA claimed that Dr. Turkel had not provided “adequate labeling” for his Down’s syndrome cure. The FDA didn’t specify what was wrong with Dr. Turkel’s labeling so Dr. Turkel was not able to fix the problem. In a communication between Dr. Turkel and the FDA in 1960, Mr. Yakowitz from the Bureau of Enforcement sent a message to Dr. Turkel saying that it was doubtful that Dr. Turkel’s medicinal formula could benefit Down’s syndrome because:
“...the condition is caused by a defect in the basic cell structure. This finding considered together with the long history of inability of medical science to find a treatment or cure for mongolism [Down Syndrome] suggests that this condition is beyond hope of successful treatment by the kind of preparations that you wish to recommend for this purpose.”
Mr. Yakowitz also stated that:
“....the proposed mixture of pentylenetetrazol with nicotinic acid is regarded as unscientific.”
Pentylenetetrazol with nicotinic acid was approved for use by various pharmaceutical companies at that time, but the FDA wanted to stall on the approval of Dr. Turkel’s Down’s syndrome medicine to reduce symptoms of the disease. They were trying to delay a possible FDA-approval of Dr. Turkel’s medicine long enough to fabricate a public hysteria about developmental delays which came about soon after with the thalidomide tragedies. After thalidomide, medical staff at the FDA got Congress to make Amendments requiring “proof” of efficacy of any new drug. “Proof”, however, was defined arbitrarily by the FDA to protect certain disease “industries” that are especially profitable.
NOTE: Readers should know that nicotinic acid, also known as vitamin B3 or niacin is sometimes also administered today a Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN) to produce Nicotinamide Adenine Diphosphate (NAD+). Rather than combining nicotinic acid and pentylenetetrazol (to improve absorption of the nicotinic acid), Down’s syndrome patients may instead benefit from taking oral NMN (which is not available in the United States) or oral NR (a suitable alternative). Down’s syndrome patients can also receive NAD+ injections or use an NAD+ nasal spray to increase levels of this vital nutrient that improves cognition significantly.
Click here to learn more about the AlivenHealthy Living Database.
By 1963, Dr. Turkel received the following communication from the FDA:"It is our opinion that it may be impossible to write suitable labeling for the efficacy of this product; in view of the cytogenetic basis of mongolism [Down’s syndrome], we recommend that you abandon work on this application."
In fact, it is nearly impossible to write labeling for the role played by each individual nutrient in Dr. Turkel’s formula because they work synergistically in the body. As such, Dr. Turkel was required to write adequate labeling for his drug’s effectiveness, but the FDA regulations were worded such that it was impossible to write adequate labeling.
In 1963, Dr. Turkel was also invited by the FDA to provide more evidence for the effectiveness of his drug, but the FDA also warned him simultaneously that it would be “difficult” for him to create a plan that the FDA would approve. One year later, the FDA sent Dr. Turkel the following order:
"You should immediately recall the drug from all clinical investigators and discontinue administering it to human beings."
Under the 1962 laws set forth by the FDA against Dr. Turkel, it would have been impossible to approve penicillin or aspirin, but by the time Dr. Turkel’s cure for Down’s syndrome was submitted for approval, Big Pharma had already taken shape to prevent the public from learning about cures for serious diseases. Rather, Big Pharma was, at this time, working to produce profitable drug industries around diseases like Down’s syndrome. As a result, Dr. Turkel’s Down syndrome cure was never approved and it never became well-known or available to the masses in the United States. However, the Russians found out about the U-Series as a potential cure for Down’s Syndrome in 1961 and adopted its use and it was widely available in both Japan and Norway since 1964. In Norway, it was dispensed by all physicians at 80 university and national hospitals for the treatment of Down’s syndrome, learning disability, and developmental delays.
Click here to read a detailed overview of Dr. Turkel's cure for Down Syndrome.
Resources:
• LifeExtension Magazine (2023). The Untapped Healing Potential of DMSO. Retrieved March 14, 2024 from https://www.lifeextension.com/magazine/2007/7/cover_dmso
• Leshin, L. (1998). Dimethyl Sulfoxide (DMSO) and Down Syndrome. Retrieved March 14, 2023 from https://www.ds-health.com/dmso.htm
• Drachmann, D. et al. (2020). Ketotic hypoglycemia in patients with Down Syndrome. Retrieved March 14, 2024 from https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmd2.12241
• Jiang, Y. et al. (2019). Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99). Retrieved March 14, 2024 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607756/
• Turkel, H. et al. (1974). Medical Amelioration of Down's Syndrome Incorporating the Orthomolecular Approach. Retrieved March 14, 2024 from http://orthomolecular.org/library/jom/1975/pdf/1975-v04n02-p102.pdf
• ISOM (2023). Henry Turkel, MD. Retrieved March 26, 2024 from https://isom.ca/profile/henry-turkel/
• Turkel, et al. (1975). Intellectual Improvement of A Retarded Patient Treated with the "U" Series. Retrieved March 26, 2024 from http://orthomolecular.org/library/jom/1984/pdf/1984-v13n04-p272.pdf
• Irgens, H. U. et al. (2015). Glycogenin-2 is dispensable for liver glycogen synthesis and glucagon-stimulated glucose release. Retrieved March 26, 2024 from https://pubmed.ncbi.nlm.nih.gov/25751106/
You might be interested in these e-Books
FREE CANCER CURE CATALOG - VOLUME 1
After signing up, you'll receive an email containing a link to download your free e-Book. In the future, you'll receive occasional emails FROM US ONLY about topics related to health and self-care. We will not sell your email address. We will not share your email address. It's only for our use and you can opt-out any time simply by clicking a link at the bottom of the email.
We're currently giving away the first volume of The Cancer Cure Catalog, the first of a 4 volume reference set of scientifically proven cancer cures complete with a resource list of scientific articles and testimonials for each treatment listed.
Fill out the form below to receive your free e-Book!